학술논문
MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)
Document Type
Abstract
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S390-S390
Subject
Language
ISSN
2152-2650